Cell Therapy Next Current Issue

The following articles appeared in the print edition of Cell Therapy Next.

Table of Contents

• COVID-19 prevention must extend beyond vaccines for patients receiving cell therapies Drew Amorosi
• FDA approves Carvykti as second CAR T-cell therapy for advanced multiple myeloma Drew Amorosi
• FDA places clinical hold on Legend Biotech’s CAR-T for T-cell lymphoma
• FDA approves Yescarta as second-line therapy for large B-cell lymphoma Drew Amorosi
• Investigational therapy for B-cell malignancies offers three targets in one CAR T cell Drew Amorosi; Reshmi Parameswaran, MS, PhD
• Lack of awareness, limited sites hinder CAR-T trials for younger patients with cancer Drew Amorosi
• From referral to infusion: Accelerating the CAR-T process Drew Amorosi
• CAR T-cell therapy trial paused after two patient deaths
• Early intrathecal therapy shows promise for managing neurotoxicity related to CAR-T Drew Amorosi
• Personalized cell therapy shows promise in metastatic breast cancer Drew Amorosi
• Researchers develop test to predict durable remissions after CAR-T for lymphoma Drew Amorosi
• Axi-cel CAR-T significantly improves EFS among older patients with non-Hodgkin lymphoma Drew Amorosi
• Next breakthrough for CAR T cells may come in acute myeloid leukemia Drew Amorosi
• Nonviral CAR-T is ‘remarkably safe’ and clinically active in B-cell ALL Drew Amorosi
• Scoring system predicts infection risk, treatment outcomes after CAR-T Drew Amorosi